Search Results

Business

Benson Hill Reports Solid Full-Year 2023 Financial Results, Strengthens Balance Sheet

Benson Hill, Inc. (NYSE:BHIL, the “Company” or “Benson Hill”), an ag-tech company unlocking the natural genetic diversity of plants, today announced operating and financial results for the year ended December 31, 2023.

March 14, 2024

·

25 min read

Business

Benson Hill Announces Date of Fourth Quarter and Full Year Earnings Release

Benson Hill, Inc. (NYSE: BHIL, the “Company” or “Benson Hill”), an ag tech company unlocking the natural genetic diversity of plants, announced today that it will release its financial results for the full year and fourth quarter ending Dec. 31, 2023, before the market opens on Thursday, March 14, 2024.

February 7, 2024

·

1 min read

BioMidwest

Benson Hill Announces Gains in Soybean Breeding Program; Introduces Five 2024 Soybean Varieties Delivering Higher Protein and Improved Yield Potential

Benson Hill, Inc., an ag tech company unlocking the natural genetic diversity of plants, announced that recent advances in its soybean breeding program will drive the doubling of its seed portfolio by 2025.

January 4, 2024

·

9 min read

Business

Benson Hill Revises Second Quarter 2022 Earnings Release Call Time

Benson Hill, Inc., a food tech company unlocking the natural genetic diversity of plants, announced a revised time for its second quarter earnings call and webcast to 8 a.m. Eastern Time from 8:30 a.m. Eastern Time on Monday, Aug. 8, 2022.

June 30, 2022

·

1 min read

Biosenta Announces Engagement of Oak Hill Financial Inc.

Biosenta Inc. (CSE: ZRO) (“Biosenta” or the “Company”) announces that it has entered into an agreement with Oak Hill Financial Inc. (“Oak Hill”) to provide business

January 11, 2024

·

3 min read

Lone Star Bio

7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the Clinic

7 Hills Pharma Inc., a clinical-stage pharma company leveraging a novel mechanism of action to safely enhance the effectiveness of cancer immunotherapies, was awarded $4.7 million from the Cancer Prevention and Research Institute of Texas to support its cell/gene therapy development program.

June 3, 2024

·

5 min read

Policy

Hemostemix Announces Engagement of Oak Hill Asset Management Inc.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is pleased to announce the non-exclusive engagement of Oak Hill Asset Management Inc. (“OHAM”), an Exempt Market Dealer to provide capital markets advice related to the Company’s capital markets strategy.

March 8, 2024

·

7 min read

Press Releases

Oak Hill Bio Announces Promotion of Josh Distler to Chief Executive Officer and Additional Updates to Executive Team and Board

October 7, 2024

·

5 min read

Business

Torus Biosystems Announces Appointment of Nancy Hill to Board of Directors

Torus Biosystems today announced the appointment of Nancy Hill as lead Independent Director to the Company’s Board of Directors.

October 12, 2022

·

3 min read

Press Releases

T2 Biosystems Announces Third Quarter 2024 Financial Results

November 15, 2024

·

10 min read